{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:00:49Z","timestamp":1751569249744,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202345","81771762, and 82271838"],"award-info":[{"award-number":["81202345","81771762, and 82271838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Macrophage activation syndrome (MAS), an example of secondary hemophagocytic lymphohistiocytosis, is a potentially fatal complication of rheumatic diseases. We aimed to study the clinical and laboratory characteristics, treatment schemes, and outcomes of different rheumatic disorders associated with MAS in children. Early warning indicators of MAS have also been investigated to enable clinicians to make a prompt and accurate diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty-five patients with rheumatic diseases complicated by MAS were enrolled between January 2017 and December 2022. Clinical and laboratory data were collected before disease onset, at diagnosis, and after treatment with MAS, and data were compared between patients with systemic juvenile idiopathic arthritis (sJIA), Kawasaki disease (KD), and systemic lupus erythematosus (SLE). A random forest model was established to show the importance score of each variable with a significant difference.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Most (81.8%) instances of MAS occurred during the initial diagnosis of the underlying disease. Compared to the active stage of sJIA, the platelet count, erythrocyte sedimentation rate, and fibrinogen level in sJIA-MAS were significantly decreased, whereas ferritin, ferritin\/erythrocyte sedimentation rate, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and D-dimer levels were significantly increased. Ferritin level, ferritin\/erythrocyte sedimentation rate, and platelet count had the greatest predictive value for sJIA-MAS. The level of IL-18 in the sJIA-MAS group was significantly higher than in the active sJIA group, whereas IL-6 levels were significantly lower. Most patients with MAS were treated with methylprednisolone pulse combined with cyclosporine, and no deaths occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Thrombocytopenia, ferritin levels, the ferritin\/erythrocyte sedimentation rate, and elevated aspartate aminotransferase levels can predict the occurrence of MAS in patients with sJIA. Additionally, our analysis indicates that IL-18 plays an important role in the pathogenesis of MAS in sJIA-MAS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-024-00991-3","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:02:30Z","timestamp":1716454950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases"],"prefix":"10.1186","volume":"22","author":[{"given":"Shuoyin","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-9390","authenticated-orcid":false,"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"991_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","volume":"29","author":"A Ravelli","year":"2015","unstructured":"Ravelli A, Dav\u00ec S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29:927\u201341. https:\/\/doi.org\/10.1016\/j.hoc.2015.06.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289\u201398. https:\/\/doi.org\/10.1038\/gene.2012.3.","journal-title":"Genes Immun"},{"key":"991_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1586\/1744666X.2015.1058159","volume":"11","author":"RQ Cron","year":"2015","unstructured":"Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;11:1043\u201353. https:\/\/doi.org\/10.1586\/1744666X.2015.1058159.","journal-title":"Expert Rev Clin Immunol"},{"key":"991_CR4","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133\u20138. PMID:17343315.","journal-title":"J Rheumatol"},{"key":"991_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12519-008-0018-6","volume":"4","author":"HS Zeng","year":"2008","unstructured":"Zeng HS, Xiong XY, Wei YD, Wang HW, Luo XP. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2008;4:97\u2013101. https:\/\/doi.org\/10.1007\/s12519-008-0018-6.","journal-title":"World J Pediatr"},{"key":"991_CR6","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160\u20139. https:\/\/doi.org\/10.1002\/art.38802.","journal-title":"Arthritis Rheumatol"},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"e000161","DOI":"10.1136\/rmdopen-2015-000161","volume":"2","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2:e000161. https:\/\/doi.org\/10.1136\/rmdopen-2015-000161.","journal-title":"RMD Open"},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. https:\/\/doi.org\/10.3389\/fimmu.2019.00119.","journal-title":"Front Immunol"},{"key":"991_CR9","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66:3486\u201395. https:\/\/doi.org\/10.1002\/art.38793.","journal-title":"Arthritis Rheumatol"},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","volume":"49","author":"SJ Vastert","year":"2010","unstructured":"Vastert SJ, van Wijk R, D\u2019Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatol (Oxf Engl). 2010;49:441\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kep418.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"991_CR11","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1002\/art.23734","volume":"58","author":"K Zhang","year":"2008","unstructured":"Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892\u20136. https:\/\/doi.org\/10.1002\/art.23734.","journal-title":"Arthritis Rheum"},{"key":"991_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/eci.09.58","volume":"6","author":"S Gupta","year":"2010","unstructured":"Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137\u201354. https:\/\/doi.org\/10.1586\/eci.09.58.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"991_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0961203314552290","volume":"24","author":"R Tripathy","year":"2015","unstructured":"Tripathy R, Panda AK, Das BK. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE. Lupus. 2015;24(1):82\u20139. https:\/\/doi.org\/10.1177\/0961203314552290.","journal-title":"Lupus"},{"issue":"2","key":"991_CR14","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132. PMID: 14760812.","journal-title":"J Rheumatol"},{"key":"991_CR15","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000145143.19711.78","volume":"110","author":"JW Newburger","year":"2004","unstructured":"Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747\u201371. https:\/\/doi.org\/10.1161\/01.CIR.0000145143.19711.78.","journal-title":"Circulation"},{"issue":"8","key":"991_CR16","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, et al. Derivation and validation of the systemic Lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheum"},{"key":"991_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566\u201376. https:\/\/doi.org\/10.1002\/art.39332.","journal-title":"Arthritis Rheumatol"},{"key":"991_CR18","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/art.24883","volume":"60","author":"A Parodi","year":"2009","unstructured":"Parodi A, Dav\u00ec S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388\u201399. https:\/\/doi.org\/10.1002\/art.24883.","journal-title":"Arthritis Rheum"},{"key":"991_CR19","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943\u201354. https:\/\/doi.org\/10.1002\/art.41073.","journal-title":"Arthritis Rheumatol"},{"key":"991_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jpeds.2021.02.008","volume":"235","author":"L Guo","year":"2021","unstructured":"Guo L, Xu Y, Qian X, et al. Sudden hypotension and increased serum Interferon-\u03b3 and Interleukin-10 predict early macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Pediatr. 2021;235:203\u2013e2113. https:\/\/doi.org\/10.1016\/j.jpeds.2021.02.008.","journal-title":"J Pediatr"},{"key":"991_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OARRR.S151013","volume":"10","author":"B Lerkvaleekul","year":"2018","unstructured":"Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117\u201328. https:\/\/doi.org\/10.2147\/OARRR.S151013.","journal-title":"Open Access Rheumatol"},{"key":"991_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12519-020-00360-6","volume":"16","author":"SB Han","year":"2020","unstructured":"Han SB, Lee SY. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches. World J Pediatr. 2020;16:566\u201374. https:\/\/doi.org\/10.1007\/s12519-020-00360-6.","journal-title":"World J Pediatr"},{"issue":"3","key":"991_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00296-020-04763-6","volume":"41","author":"R Naveen","year":"2021","unstructured":"Naveen R, Jain A, Muhammed H, et al. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities. Rheumatol Int. 2021;41(3):625\u201331. https:\/\/doi.org\/10.1007\/s00296-020-04763-6.","journal-title":"Rheumatol Int"},{"issue":"6","key":"991_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/acr2.11048","volume":"1","author":"EMA Eloseily","year":"2019","unstructured":"Eloseily EMA, Minoia F, Crayne CB, Beukelman T, Ravelli A, Cron RQ. Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2019;1(6):345\u20139. https:\/\/doi.org\/10.1002\/acr2.11048.","journal-title":"ACR Open Rheumatol"},{"key":"991_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12098-015-1877-1","volume":"83","author":"ES Sen","year":"2016","unstructured":"Sen ES, Clarke SL, Ramanan AV. Macrophage activation syndrome. Indian J Pediatr. 2016;83:248\u201353. https:\/\/doi.org\/10.1007\/s12098-015-1877-1.","journal-title":"Indian J Pediatr"},{"key":"991_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/rheumatology\/keaa299","volume":"60","author":"M Mizuta","year":"2021","unstructured":"Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y, et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatol (Oxf Engl). 2021;60:231\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keaa299.","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"13","key":"991_CR27","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442\u201355. https:\/\/doi.org\/10.1182\/blood-2017-12-820852.","journal-title":"Blood"},{"key":"991_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1182\/blood-2018-02-828186","volume":"131","author":"KL McClain","year":"2018","unstructured":"McClain KL, Allen CE. Fire behind the fury: il-18 and MAS. Blood. 2018;131:1393\u20134. https:\/\/doi.org\/10.1182\/blood-2018-02-828186.","journal-title":"Blood"},{"key":"991_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc\u2019H C, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatol (Oxf Engl). 2020;59:361\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kez282.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"991_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10067-012-1998-0","volume":"31","author":"CI Lin","year":"2012","unstructured":"Lin CI, Yu HH, Lee JH, Wang LC, Lin YT, Yang YH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31:1223\u201330. https:\/\/doi.org\/10.1007\/s10067-012-1998-0.","journal-title":"Clin Rheumatol"},{"key":"991_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatol (Oxf Engl). 2011;50:417\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keq218.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"991_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","volume":"10","author":"W Xiong","year":"2014","unstructured":"Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97\u2013107. https:\/\/doi.org\/10.1038\/nrrheum.2013.157.","journal-title":"Nat Rev Rheumatol"},{"key":"991_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326\u201334. https:\/\/doi.org\/10.1002\/art.41103.","journal-title":"Arthritis Rheumatol"},{"key":"991_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/mr\/roab119","volume":"32","author":"J Wu","year":"2022","unstructured":"Wu J, Sun L, Tang X, Zheng Q, Guo L, Xu L, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome. Mod Rheumatol. 2022;32:1114\u201321. https:\/\/doi.org\/10.1093\/mr\/roab119.","journal-title":"Mod Rheumatol"},{"key":"991_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82:857\u201365. https:\/\/doi.org\/10.1136\/ard-2022-223739.","journal-title":"Ann Rheum Dis"},{"key":"991_CR36","doi-asserted-by":"publisher","first-page":"bcr2017221347","DOI":"10.1136\/bcr-2017-221347","volume":"2017","author":"Z Junga","year":"2017","unstructured":"Junga Z, Stitt R, Tracy C, Keith M. Novel use of Rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus. BMJ Case Rep. 2017;2017:bcr2017221347. https:\/\/doi.org\/10.1136\/bcr-2017-221347.","journal-title":"BMJ Case Rep"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-024-00991-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:12:50Z","timestamp":1716455570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-024-00991-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1186\/s12969-024-00991-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"type":"electronic","value":"1546-0096"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"5 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Children\u2019s Hospital of Nanjing Medical University (202008041-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}